Anemia in the Oncology Patient: Cognitive Function and Cancer

Cancer Nursing

Volumn 26, Issue 6 SUPPL., 2003, Pages

  Cunningham, Regina S ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Cancer related anemia; Cognitive function and chemotherapy; Darbepoetin; Epoetin alfa; Erythropoietin replacement therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ERYTHROPOIETIN; FLUOROURACIL; HEMOGLOBIN; IRON; METHOTREXATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TAMOXIFEN; THIOTEPA;

AGING; ALERTNESS; ANEMIA; BLOOD TRANSFUSION; BRAIN HYPOXIA; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; DISEASE EXACERBATION; DROWSINESS; ERYTHROPOIESIS; HEADACHE; HUMAN; MEMORY; MENTAL CONCENTRATION; NEUROPROTECTION; PRIORITY JOURNAL; QUALITY OF LIFE; TINNITUS; VERTIGO;

AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; COGNITION DISORDERS; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; MALE; NEOPLASMS;

EID: 0346750822     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002;20:4083-4107.
2. Gillespie TW. Anemia in cancer: therapeutic implications and interventions. Cancer Nurs. 2003;26:119-128.
3. Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol. 2001;28 (suppl 8):7-14.
4. Bender CM. Cognitive dysfunction associated with cancer and cancer therapy. Medsurg Nurs. 1995;4:398-400.
5. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616-1634.
6. Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol. 1998;25(suppl 7):2-6.
7. National Anemia Action Council. Anemia and cancer. Available at: http://www.anemia.org/pdf/mon_Anemia_and_Cancer.pdf. Accessed March 10, 2003.
8. Bender CM, Paraska KK, Sereika SM, Ryan CM, Berga SL. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manage. 2001;21:407-424.
9. Corea AL. Case management of the anemic patient. Epoetin alfa: focus on cognitive function. ANNA J. 1993;20:350-353.
10. Nissenson AR. Epoetin and cognitive function. Am J Kidney Dis. 1992;20(suppl I):21-24.
11. Schagen SB, van Dam FSAM, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85:640-650.
12. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20:485-493.
13. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IE Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18:2695-2701.
14. van Dam FSAM, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90:210-218.
15. Glaspy JA, Jadeja J, Justice G, et al. Randomized, active-controlled, phase 1/2 dose-escalation study of NESP administered weekly and every 2 weeks in patients with solid tumors [abstract]. Proc Am Soc Clin Oncol. 2001. Abstract 1546.
16. Grimm G, Stockenhuber F, Schneeweiss B, Madl C, Zeitlhofer J, Schneider B. Improvement of brain function in hemodialysis patients treated with erythropoietin. Kidney Int. 1990;38:480-486.
17. Marsh JT, Brown WS, Wolcott D, et al. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int. 1991;39:155-163.
18. O'Shaughnessy J, Vukelja S, Savin M, et al. Effects of epoetin alfa (Procrit) on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy: a double-blind, randomized, placebo-controlled trial [abstract]. Proc Am Soc Clin Oncol. 2002. Abstract 1449.
19. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B, for the Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865-2874.
20. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001;19:2875-2882.
21. Vansteenkiste J, Pirker R, Massuti B, et al, for the Aranesp 980297 Study Group. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94:1211-1220.
22. National comprehensive cancer network (NCCN) practice guidelines in oncology. Available at: http://www.nccn.org/physician_gls/f_guidelines. html. Accessed March 10, 2003.
23. Bernaudin M, Bellail A, Marti HH, et al. Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia. 2000;30:271-278.
24. Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R. A novel site of erythropoietin production: oxygen-dependent production in cultured rat astrocytes. J Biol Chem. 1994;269:19488-19493.
25. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience. 1997;76:105-116.
26. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000;97:10526-10531.
27. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA. 1998;95:4635-4640.
28. Sadamoto Y, Igase K, Sakanaka M, et al. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun. 1998;253:26-32.